Brian L. Hodous

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael P. Sheets et al. · Cancer Discovery · 2015 · 305 citations · Full text

Enantioselective Staudinger Synthesis of β-Lactams Catalyzed by a Planar-Chiral Nucleophile

Brian L. Hodous, Gregory C. Fu · Journal of the American Chemical Society · 2002 · 245 citations

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica N Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 209 citations

Catalytic Asymmetric Staudinger Reactions to Form β-Lactams:  An Unanticipated Dependence of Diastereoselectivity on the Choice of the Nitrogen Substituent

Elaine C. Lee, Brian L. Hodous, E. Bergin et al. · Journal of the American Chemical Society · 2005 · 190 citations

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 136 citations · Full text

Novel Therapy, Medicine, Tyrosine Kinase +14